Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248813 | 1.00 | MAOB (0.41) | MAOBACHEBCHEMAOAKMT2A | |
| SCHEMBL7250197 | 0.83 | NR1H4 (0.40) | MAOBACHEBCHEMAOAKMT2A | |
| SCHEMBL7250201 | 0.83 | NR1H4 (0.40) | MAOBACHEBCHEMAOAKMT2A | |
| SCHEMBL6949825 | 0.81 | ACHE (0.45) | MAOBACHEBCHEMAOARAB9A | |
| SCHEMBL5107687 | 0.80 | KMT2A (0.42) | MAOBMAOAKMT2APDK2MAPT | |
| SCHEMBL5107694 | 0.80 | KMT2A (0.42) | MAOBMAOAKMT2APDK2MAPT | |
| SCHEMBL5113624 | 0.80 | KMT2A (0.42) | MAOBMAOAKMT2APDK2MAPT | |
| SCHEMBL27544928 | 0.79 | KMT2A (0.32) | MAOBKMT2AMAPT | |
| SCHEMBL8796826 | 0.76 | MAOB (0.48) | MAOBACHEBCHEMAOAMAPT | |
| SCHEMBL7454718 | 0.74 | MGAM (0.58) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | claimed |
| EP-1124807-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | claimed |
| WO-1999016758-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-08 | — | — | WO | claimed |
| US-6664411-B2 | Beta-aryl/alpha-oxysubstituted alkylcarboxylic acids of 4-oxo-or thiocarbonylchromenes or thiochromenes; antiobesity, -cholesterol - diabetic agents; agonists of peroxisome proliferator activated receptors; kidney disorders | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-16 | — | — | US | disclosed |
| US-6331627-B1 | Intermediates of benzoxazinone derivatives and preparation thereof | REDDY'S LABORATORIES LTD. (IN) | 2001-12-18 | — | — | US | disclosed |
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1124807-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| US-6130214-A | Benzothiazin and benzoxazin derivatives; their preparation and uses | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-10-10 | — | — | US | disclosed |
| WO-1999016758-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP51A1 | MAOB 870/4885ACHE 3693/4885BCHE 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.